Oramed Pharmaceuticals, Inc. (ORMP)
4.13
+0.01
(+0.24%)
USD |
NASDAQ |
Oct 23, 16:00
4.14
+0.01
(+0.24%)
After-Hours: 20:00
Oramed Pharmaceuticals Enterprise Value : 120.75M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 120.75M |
| October 22, 2026 | 120.34M |
| October 21, 2026 | 121.16M |
| October 20, 2026 | 121.57M |
| October 19, 2026 | 117.86M |
| October 16, 2026 | 118.27M |
| October 15, 2026 | 122.81M |
| October 14, 2026 | 121.16M |
| October 13, 2026 | 122.40M |
| October 12, 2026 | 126.53M |
| October 09, 2026 | 129.01M |
| October 08, 2026 | 123.64M |
| October 07, 2026 | 130.66M |
| October 06, 2026 | 131.08M |
| October 05, 2026 | 138.10M |
| October 02, 2026 | 135.62M |
| October 01, 2026 | 135.21M |
| September 30, 2026 | 143.06M |
| September 29, 2026 | 143.88M |
| September 28, 2026 | 146.36M |
| September 25, 2026 | 145.54M |
| September 24, 2026 | 148.02M |
| September 23, 2026 | 145.12M |
| September 22, 2026 | 146.36M |
| September 21, 2026 | 144.30M |
| Date | Value |
|---|---|
| September 18, 2026 | 145.95M |
| September 17, 2026 | 143.06M |
| September 16, 2026 | 140.99M |
| September 15, 2026 | 140.99M |
| September 14, 2026 | 143.06M |
| September 11, 2026 | 142.65M |
| September 10, 2026 | 146.78M |
| September 09, 2026 | 147.60M |
| September 08, 2026 | 155.87M |
| September 04, 2026 | 157.11M |
| September 03, 2026 | 153.80M |
| September 02, 2026 | 159.58M |
| September 01, 2026 | 150.49M |
| August 31, 2026 | 157.52M |
| August 28, 2026 | 157.93M |
| August 27, 2026 | 160.82M |
| August 26, 2026 | 170.74M |
| August 25, 2026 | 165.37M |
| August 24, 2026 | 149.26M |
| August 21, 2026 | 148.84M |
| August 20, 2026 | 148.02M |
| August 19, 2026 | 148.02M |
| August 18, 2026 | 147.60M |
| August 17, 2026 | 138.93M |
| August 14, 2026 | 135.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 78.16M |
| Total Expenses (Quarterly) | -78.16M |
| EPS Diluted (Quarterly) | 1.839 |
| Earnings Yield | 99.53% |
| Normalized Earnings Yield | 25.38 |